Shelly Tartakover-Matalon

Dr. Shelly Tartakover-Matalon

Autoimmune research Laboratory, Meir Medical Center, Israel
+1

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2001 in American Journal of Reproductive Immunology
Verified
Journal Article
Closed access
PDF file
STShelly Tartakover-Matalon
Shelly Tartakover-Matalon
MBM. Blank
M. Blank
Asher OrnoyAsher Ornoy
Asher Ornoy
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld

11 February 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TNTimna Naftali
Timna Naftali
LSLihi Bar-Lev Schleider
Lihi Bar-Lev Schleider
FBFabiana Scklerovsky Benjaminov
Fabiana Scklerovsky Benjaminov
FKFred Meir Konikoff
Fred Meir Konikoff
STShelly Tartakover-Matalon
Shelly Tartakover-Matalon
YRYehuda Ringel
Yehuda Ringel
Background: Cannabis is often used by patients with ulcerative colitis, but controlled studies are few. We aimed to assess the effect of cannabis in improving clinical and inflammatory outcomes in ulcerative colitis patients.Methods: In a double-blind, randomized, placebo-controlled trial, patients received either cigarettes containing 0.5 g of dried cannabis flowers with80mgTetrahydrocannabinol (THC)or placebo cigarettes for 8 weeks. Parameters of disease including Lichtiger disease activity index, C reactive protein (CRP), calprotectin, Mayo endoscopic score and quality of life (QOL) were assessed before, during and after treatment.Results: The study included 32 patients. Mean age was 30 years, 14 (43%) females. Lichtiger index improved in the cannabis group from 10.9 (IQR 9–14) to5 (IQR 1–7), (p<0.000), and in the placebo group from 11 (IQR 9–13) to 8 (IQR 7–10)(p = 0.15, p between groups 0.001). QOL improved in the cannabis group from 77±4 to 98±20 (p = 0.000) but not in the placebo group (78±3 at week 0 and 78±17 at week 8;p = 0.459; p between groups 0.007). Mayo endoscopic score changed in the cannabis group from 2.13±1 to 1.25±2 (p = 0.015) and in the placebo group from 2.15±1to 1.69±1 (p = 0.367, p between groups 0.17).Conclusion: Short term treatment with THC rich cannabis induced clinical remission and improved quality of life in patients with mild to moderately active ulcerative colitis. However, these beneficial clinical effects were not associated with significant anti-inflammatory improvement in the Mayo endoscopic score or laboratory markers for inflammation.(clinicaltrials.gov NCT01040910).

1 February 2012 in Laboratory Investigation
Verified
Journal Article
Closed access
OAOshrat Attar-Schneider
Oshrat Attar-Schneider
LDLiat Drucker
Liat Drucker
VZVictoria Zismanov
Victoria Zismanov
STShelly Tartakover-Matalon
Shelly Tartakover-Matalon
GRGloria Rashid
Gloria Rashid
MLMichael Lishner
Michael Lishner

15 June 2005 in Human Reproduction
Verified
Journal Article
Open access
PDF file
IKI. Kenis
I. Kenis
STShelly Tartakover-Matalon
Shelly Tartakover-Matalon
NCN. Cherepnin
N. Cherepnin
LDL. Drucker
L. Drucker
AFA. Fishman
A. Fishman
MLM. Lishner
M. Lishner
BACKGROUND: Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMG-CoA reductase), the rate-limiting enzyme of the mevalonate pathway, and have been used successfully in the treatment of hypercholesterolaemia. Animal models have provided evidence for the teratogenic effects of statins on pregnancy outcome. Thus statins are contraindicated during pregnancy. However, conflicting data are available from inadvertent use of statins in human pregnancy. Therefore we decided to explore the effects of simvastatin on the placenta in an in vitro human placental model. METHODS: Human first trimester placental explants that were grown on matrigel were exposed to medium supplemented with simvastatin. Migration of extravillous trophoblast cells was assessed by visual observation. Proliferative and apoptotic events of the trophoblast cells were assesed by immunohistochemical examination using anti-Ki67 and anti-activated caspase-3 antibodies respectively. Hormone levels were measured. RESULTS: Simvastatin sharply inhibited migration of extravillous trophoblast cells from the villi to the matrigel (P < 0.05). Moreover, simvastatin inhibited half of the proliferative events in the villi (P < 0.05) and increased apoptosis of cytotrophoblast cells compared to control. Moreover, simvastatin significantly decreased secretion of progesterone from the placental explants (P < 0.01). CONCLUSION: Simvastatin adversely affects human first trimester trophoblast.

1 September 2014 in Cellular Signalling
Verified
Journal Article
Closed access
OAOshrat Attar-Schneider
Oshrat Attar-Schneider
LDLiat Drucker
Liat Drucker
VZVictoria Zismanov
Victoria Zismanov
STShelly Tartakover-Matalon
Shelly Tartakover-Matalon
MLMichael Lishner
Michael Lishner

31 August 2021 in Frontiers in Endocrinology
Verified
Journal Article
Open access
STShelly Tartakover-Matalon
Shelly Tartakover-Matalon
SAShahar Azar
Shahar Azar
DMDavid Meiri
David Meiri
RHRivka Hadar
Rivka Hadar
ANAlina Nemirovski
Alina Nemirovski
TNTimna Naftali
Timna Naftali
Background: Inflammatory bowel diseases (IBDs) are chronic, idiopathic, inflammatory, gastrointestinal disorders. The endocannabinoid system may have a role in the pathogenesis of IBD. We aimed to assess whether cannabis treatment influences endocannabinoids (eCBs) level and clinical symptoms of IBD patients.Methods: Blood samples and biopsies were taken from IBD patients treated by either cannabis or placebo for 8 weeks. Immunohistochemistry for N-acyl-phosphatidylethanolamine-selective phospholipase D (NAPE-PLD) and fatty acid amide hydrolase (FAAH) expression was done on colon biopsies, and sample levels of anandamide (AEA), eCB2-arachidonylglycerol (2-AG), arachidonic acid (AA), palmitoylethanolamine (PEA), and oleoylethanolamine (OEA) were measured in patient’s sera before and after cannabis treatment. Caco-2 cells were cultured with extracts of cannabis with/without tetrahydrocannabinol (THC) and their proteins extracted, and Western blotting for NAPE-PLD and FAAH expression was done.Results: Thirteen patients with Crohn’s disease (CD) and nine patients with ulcerative colitis (UC) were treated with cannabis. Seventeen patients with CD and 10 with UC served as placebo groups. In all CD patients, the levels of eCBs remained unaltered during the treatment period. In UC patients treated with placebo, but not in those treated with cannabis, the levels of PEA, AEA, and AA decreased significantly. The percent reduction in bowel movements was negatively correlated with changes observed in the circulating AEA and OEA, whereas improvement in quality of life was positively correlated with the levels of 2-AG. In the biopsies from UC patients, FAAH levels increased over the study period. In Caco-2 cells, both cannabis extracts increased NAPE-PLD levels but reduced FAAH expression levels.Conclusion: Our study supports the notion that cannabis use affects eCB “tone” in UC patients and may have beneficial effects on disease symptoms in UC patients.